Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vivus Inc (VVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 119,305
  • Shares Outstanding, K 105,580
  • Annual Sales, $ 124,260 K
  • Annual Income, $ 23,300 K
  • 36-Month Beta 0.77
  • Price/Sales 0.95
  • Price/Cash Flow 2.67
  • Price/Book 6.58

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.99 +14.14%
on 05/16/17
1.14 -0.88%
on 05/26/17
+0.11 (+10.78%)
since 04/26/17
3-Month
0.99 +14.14%
on 05/16/17
1.25 -9.60%
on 03/09/17
-0.01 (-0.88%)
since 02/24/17
52-Week
0.93 +21.51%
on 08/02/16
1.47 -23.13%
on 12/07/16
-0.11 (-8.87%)
since 05/26/16

Most Recent Stories

More News
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.

ALDX : 4.75 (unch)
VVUS : 1.13 (+0.89%)
ZTS : 62.61 (+0.05%)
RHHBY : 33.9600 (-1.19%)
Puma Soaring After Neratinib FDA Panel Win, Time to Buy?

Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast...

VVUS : 1.13 (+0.89%)
PBYI : 79.75 (+2.18%)
ZTS : 62.61 (+0.05%)
RHHBY : 33.9600 (-1.19%)
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data

Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study

ALDX : 4.75 (unch)
VVUS : 1.13 (+0.89%)
ZTS : 62.61 (+0.05%)
INO : 7.88 (-1.38%)
Aerie's Ophthalmic Candidate Positive in Registration Trial

Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.

AERI : 55.90 (+3.04%)
VVUS : 1.13 (+0.89%)
AGN : 223.12 (-0.55%)
PFE : 32.14 (-0.06%)
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients...

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
MEIP : 2.12 (+7.61%)
BMY : 53.97 (-0.77%)
Regeneron Presents Positive Phase II Data on HoFH Candidate

Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific...

VVUS : 1.13 (+0.89%)
MDCO : 39.14 (-0.63%)
ALNY : 65.80 (-5.32%)
REGN : 455.17 (-0.12%)
Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session

Puma Biotechnology, Inc. (PBYI) moved big last session, as its shares rose over 30% on the day.

VVUS : 1.13 (+0.89%)
PBYI : 79.75 (+2.18%)
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair

Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.

ALDX : 4.75 (unch)
VVUS : 1.13 (+0.89%)
HZNP : 10.20 (+2.31%)
ZTS : 62.61 (+0.05%)
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler

Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.

TBPH : 37.47 (+0.32%)
MYL : 39.72 (-0.28%)
VVUS : 1.13 (+0.89%)
NVS : 80.63 (-0.89%)
Achaogen's Plazomicin Gets Breakthrough Therapy Designation

Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant...

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
AKAO : 21.64 (-1.99%)
MEIP : 2.12 (+7.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity...

See More

Support & Resistance

2nd Resistance Point 1.16
1st Resistance Point 1.14
Last Price 1.13
1st Support Level 1.11
2nd Support Level 1.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.